# A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

> **NCT05109702** · PHASE3 · COMPLETED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 260 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** 0.25% Tanfanercept Ophthalmic Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05109702
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-05-06
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109702, "A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05109702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*